BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415-506-6700
http://www.biomarin.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2,849

Key Executives

NameTitlePayExercisedYear Born
Mr. Jean-Jacques Bienaimé M.B.A., MBAChairman & CEO2.92M11.73M1953
Mr. Daniel K. SpiegelmanExec. VP & CFO1.1MN/A1959
Dr. Robert A. BaffiExec. VP of Technical Operations1.11M587.96k1955
Mr. Jeffrey Robert AjerExec. VP & Chief Commercial Officer1.03M261.46k1962
Dr. Henry J. FuchsPres of Worldwide R&D1.38M3.02M1958
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Corporate Governance

BioMarin Pharmaceutical Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.